 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire THOUSAND OAKS, Calif., Oct. 20, 2022 TAVNEOS(avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio...

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx shareholders approve $4.7B merger with Amgen

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx...

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx, Inc. (NASDAQ:CCXI Get Rating) hit a new 52-week high on Monday . The stock traded as high as $51.90 and last traded at $51.86, with a volume of 12149 shares. The stock had previously closed at $51.86. Analyst Ratings Changes Several brokerages recently weighed in on CCXI. Canaccord ...

ChemoCentryx (NASDAQ:CCXI) Reaches New 1-Year High at $51.90

Shares of ChemoCentryx, Inc. (NASDAQ:CCXI Get Rating) have received a consensus rating of Hold from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has ...

ChemoCentryx, Inc. (NASDAQ:CCXI) Receives $64.17 Average PT from Analysts

ChemoCentryx, Inc. (NASDAQ:CCXI  Get Rating) has been assigned an average recommendation of Hold from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, one has ...

ChemoCentryx, Inc. (NASDAQ:CCXI) Given Consensus Rating of "Hold" by Brokerages

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two ...

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Symbols mentioned in this story: XBI, CRSP, ACAD, CCXI

 Exchange traded funds (ETFs) trade just like stocks, but instead of shares investors are actually buying and selling units. These units can be traded back and forth just like stocks, ...

SPDR S&amp;P Biotech ETF Experiences Big Outflow

This price move could be a signal that CCXI may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

ChemoCentryx (CCXI, $51.8) price may drop as it broke higher Bollinger Band on Sep 21, 2022

ChemoCentryx, Inc. (NASDAQ:CCXI  Get Rating) has earned a consensus recommendation of Hold from the nine ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a ...

Analysts Set ChemoCentryx, Inc. (NASDAQ:CCXI) Target Price at $62.43

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Watchers	11,894
52-Wk Low	$14.95
52-Wk High	$52.00

Market Cap	$3.71B
Volume (M)	2.48M
52-Wk High	$52.00
52-Wk Low	$14.95

CCXI ChemoCentryx Inc

About

Feed

News

Fundamentals